OxyContin Settlement Between Purdue, The P.F. Laboratories, Rhodes Technologies, University of Texas, Grunenthal, and Sandoz Approved

Purdue Pharma L.P. et al. v. Sandoz Inc.

Case Number: 1:11-cv-04694-SHS (Dkt.124)

Less than a week before he issued Findings of Fact and Conclusions of Law finding certain claims of four of the following five patents invalid (Dkt. 149), Judge Stein approved the settlement between plaintiffs Purdue et al. and defendant Sandoz Inc. with respect to the U.S. Patents Nos. ­­­­7,674,799 (entitled “Oxycodone hydrochloride having less than 25 ppm 14–hydroxycodeinone”), 7,674,800 (same), 7,683,072 (same), 6,488,963 (entitled “Hot-melt extrudable pharmaceutical formulation”), and 7,776,314 (entitled “Abuse-proofed dosage system”). These patents relate to the drug oxycodone, sold by Purdue as OxyContin. Sandoz agreed that the patents were valid and enforceable against ANDA products, that these products infringed the claims asserted against it, and agreed not to make, have made, use offer to sell, sell, or import generic oxycodone products until an undisclosed terminal date. Plaintiffs agreed not to sue Sandoz for products authorized by a separate, confidential agreement.

The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.